Recent Updates
Recently added Catalysts
BIIB Negative Sentiment Score: 25/100

Biogen Inc. (Nasdaq: BIIB) Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Key Takeaway: A class action lawsuit has been filed against Biogen Inc. on behalf of investors who acquired its securities between February 3, 2022, and February 13, 2024. The lawsuit alleges that Biogen made materially false and misleading statements regarding its compliance controls, the effectiveness of its Alzheimer's treatment Leqembi, and the impact of its acquisition of Reata Pharmaceuticals. The Portnoy Law Firm is offering complimentary case evaluations for affected investors seeking to recover losses incurred during this period.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Biogen for allegedly misleading investors.
  • Claims of unlawful conduct in several foreign countries impact investor trust.
  • Concerns regarding the perceived failure of Alzheimer's treatment Leqembi.
  • Questionable implications of the Reata Pharmaceuticals acquisition on Biogen's business.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses.
LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Biogen Inc. (Nasdaq: BIIB) (“Biogen” or the “Company”) investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024.
Biogen investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-682-9993 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The action alleges that, throughout the Class Period, Biogen made materially false and misleading statements to investors related to: (1) the effectiveness of the company’s compliance controls and procedures as it was engaged in unlawful conduct in several foreign countries; (2) the purported success of the launch of an Alzheimer’s disease treatment named Leqembi; and (3) the impact that Biogen’s acquisition of Reata Pharmaceuticals, Inc. would have on Biogen’s business.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Securities Litigation

Frequently Asked Questions

Who can participate in the Biogen class action?

Individuals or entities that purchased Biogen securities between February 3, 2022, and February 13, 2024, can join.

How can investors contact the Portnoy Law Firm?

Investors can call 310-682-9993 or email lesley@portnoylaw.com for assistance.

What allegations are made against Biogen in the lawsuit?

The lawsuit claims Biogen made false statements about compliance controls and product success.

Is there a cost to evaluate my case with the law firm?

No, the Portnoy Law Firm offers a complimentary case evaluation for investors.

What is the goal of the Portnoy Law Firm for investors?

The firm aims to help investors recover losses due to corporate misconduct.

Last updated: May 29, 2024